GlioGuard develops a cost‑effective glioblastoma therapy by repurposing FDA‑approved drugs into a short‑term induction and long‑term maintenance regimen, achieving therapeutic responses in about 40% of patients. The company pairs this treatment with a companion diagnostic assay that uses molecular biomarkers to identify patients most likely to benefit, helping neuro‑oncology clinics personalize care and improve survival outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Glioblastoma (GBM) has a median survival of less than two years after surgery and standard pharmacotherapy, and most patients experience tumor relapse with limited effective treatment options. The high cost of novel therapies further restricts access for many patients and their families.
Solution
GlioGuard addresses this gap by developing a repurposed drug formulation that achieves therapeutic responses in approximately 40% of GBM patients. The formulation combines existing, clinically approved compounds into a short‑ and long‑term treatment regimen designed to improve efficacy while keeping costs low. To ensure the therapy is given to patients most likely to benefit, GlioGuard also offers a precision diagnostic test that identifies responders based on molecular or biomarker profiles. By pairing the targeted therapy with a companion diagnostic, the company aims to increase overall survival outcomes and reduce unnecessary treatment exposure.
Target Audience
Primary customers are neuro‑oncology clinics, hospital oncology departments, and specialized brain tumor treatment centers seeking affordable, evidence‑based therapies for glioblastoma patients.
Features
- Repurposed drug cocktail leveraging existing FDA‑approved agents for a cost‑effective GBM therapy
- Integrated short‑term induction phase followed by a long‑term maintenance schedule
- Companion diagnostic assay that stratifies patients into likely responders and non‑responders
- Biomarker‑driven selection criteria to personalize treatment pathways
- Clinical data supporting a 40% response rate in treated GBM cases